9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

Size: px
Start display at page:

Download "9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH"

Transcription

1 9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing the expression of several thyroid specific proteins (Tg, sodium-iodide symporter). TSH suppression (<0.1mU/L) is recommended for high-risk and intermediate-risk thyroid cancer patients Serum Tg should be measured every 6-12 months with a quantitative assessment of thyroglobulin antibodies with every measurement. Serum Tg and neck U/S may be done in patients with less than total thyroidectomy or in patients with total thyroidectomy but no RAI to eval increase in Tg over time. Suspicious lymph nodes on f/u (>5-8mm) should have FNA with Tg measurement in the needle washout fluid. PET scans have traditionally been used in Tg +, RAI scan negative patients. They may also be useful in initial staging and follow up of high-risk patients with poorly differentiated thyroid cancers unlikely to concentrate iodine, in invasive/metastatic Hurthle cell carcinoma staging and follow up. Low risk patients are unlikely to require PET scan. From Cummings: In addition to regular physical examination, thyroid hormone and TSH levels are monitored to ensure adequate suppression. Thyroglobulin levels should be closely monitored, and diagnostic radioiodine scanning should be performed. These tests should be performed annually for the first 2 years and then every 5 years for 20 years. [275] Typically, thyroglobulin levels should be less than 2 ng/ml after total thyroidectomy and radioiodine ablation therapy (<3 ng/ml if the patient is off thyroid replacement therapy). Increasing serum thyroglobulin levels are highly sensitive (97%) and specific (100%) for thyroid cancer recurrence. [276] Elevation of thyroglobulin levels warrants repeat radioiodine scanning and therapy. More recent studies have shown the sensitivity of serum thyroglobulin measurements for predicting thyroid cancer recurrence after a patient has received two injections of recombinant human TSH. [277] Depending on risk classification, additional follow-up procedures vary. The 2006 ATA guidelines recommend measurement of serum thyroglobulin and a cervical ultrasound examination in low-risk patients approximately 12 months after initial treatment with surgery and radioiodine ablation, but not additional whole-body radioiodine scans. [69] In intermediate-risk and high-risk patients, cervical ultrasound examination and diagnostic whole-body radioiodine scans are recommended every 6 to 12 months. Patients with MTCs require serial measurements of calcitonin and CEA. Suspected recurrences may also be detected with pentagastrin-stimulation test.

2 10. List prognostic factors (Ames criteria). HH From Cummings: Tumor Staging and Classification

3 Numerous staging and classification systems have been devised to stratify patients with thyroid carcinomas. These classifications have identified key patient-specific and tumor-specific characteristics that predict patient outcome. Risk-grouping has been used to focus aggressive treatment for high-risk patients and to avoid excessive treatment and its potential complications in patients with a lower risk for tumor recurrence or tumor-related death. TNM Classification The American Joint Commission on Cancer (AJCC) and the Union Internationale Contre le Cancer (UICC) adopted a tumor-node-metastasis (TNM) classification system (Table 124-1). In this system, patient age at presentation influences the clinical staging of a thyroid carcinoma. Of patients with stage I disease, 82% had a 20-year survival of nearly 100%, whereas the 5% of patients with stage IV disease experienced a 5-year survival of only 25%. [52] Table TNM Staging for Thyroid Cancer Primary Tumor (T) TX Primary tumor cannot be assessed T0 T1 T2 T3 T4a T4b No evidence of primary tumor Tumor = 2 cm in greatest dimension, limited to thyroid Tumor >2 cm and = 4 cm in greatest dimension, limited to thyroid Tumor >4 cm in greatest dimension, limited to the thyroid or Any tumor with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues) Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels All Anaplastic Carcinomas Are Considered T4 Tumors T4a Intrathyroidal anaplastic carcinoma surgically resectable T4b Extrathyroidal anaplastic carcinoma surgically unresectable Regional Lymph Nodes (N) NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Regional lymph node metastasis N1a N1b Metastasis to level VI (pretracheal, paratracheal, and prelaryngeal/delphian lymph nodes) Metastasis to unilateral, bilateral, or contralateral cervical or superior mediastinal lymph nodes Distant Metastasis (M) MX Distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis Stage Grouping Age <45 Years Age 45 Years

4 Stage Grouping Age <45 Years Age 45 Years Papillary/Follicular Stage I Any T any N M0 T1 N0 M0 Stage II T2 N0 M0 Stage III T3 N0 M0 T1-T3 N1a M0 T4a N0 M0 T4a N1a M0 T1-4a N1b M0 Medullary Stage I Stage II Stage III Anaplastic T1 N0 M0 T2 N0 M0 T3 N0 M0 T1-3 N1a M0 T4a N0 M0 T4a N1a M0 T1-4a N1b M0 T4a any N M0 From American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York: Springer; AMES In the AMES system, patient age, the presence of metastases, extent of tumor invasion, and tumor size were used to stratify patients into low-risk and high-risk groups (Table 124-2). Low-risk patients were young (men, <41 years old; women, <51 years old) without distant metastases and all older patients without extrathyroidal papillary carcinoma, without major invasion of the tumor capsule by follicular carcinoma or with a primary tumor less than 5 cm in diameter. In a review of 310 patients from , low-risk patients (89%) had a mortality of 1.8% compared with a mortality rate of 46% in high-risk patients (11%). Recurrence in low-risk patients was 5%, and in high-risk patients was 55%. [53] In DAMES, nuclear DNA content was added to the AMES system to improve riskstratification for papillary thyroid carcinoma. [54] Table Factors Used in Prognostic Classification Systems TNM AMES AGES MACIS

5 TNM AMES AGES MACIS Patient Factors Age X X X X Gender X X Tumor Factors Size X X X X Histologic grade X Histologic type X X * * Extrathyroidal spread X X X X Lymph node metastasis X Distant metastasis X X X X Incomplete resection X * AGES/MACIS classifications for papillary carcinomas only. AGES and MACIS In the original AGES system, age at diagnosis, histologic tumor grade, extent of disease at presentation, and tumor size were used to calculate a prognostic score. [55] Because of the infrequent practice of tumor grading, a more recent modification of the system eliminated histologic tumor grade and incorporated metastasis and extent of resection. The MACIS system accounts for metastasis, age at diagnosis, completeness of surgical resection, extrathyroidal invasion, and tumor size. [56] The MACIS score is calculated as follows: Patients were stratified by their prognostic scores into four groups with statistically significant differences in 20-year disease-specific mortality. Other risk-classification systems with similar diagnostic criteria have been described. [57-59] Although numerous multivariable prognostic scoring systems have been developed, none is universally accepted. Additionally, none of these classifications has shown clear superiority, and application of these systems to a single population has shown incompatible findings compared with the original studies. [59,60] These systems do not apply to patients with poorly differentiated and more aggressive thyroid carcinomas. Nevertheless, some general conclusions can be drawn from these studies regarding the prognosis of patients with well-differentiated thyroid carcinomas. Low risk for tumor recurrence and diseasespecific mortality is noted in patients who are younger at diagnosis, have smaller primary tumors that lack extrathyroidal extension or regional/distant metastases, and have complete gross resection of disease at the initial surgery. Delay in treatment negatively affects prognosis. The most significant overall indicator of a poor prognosis is distant metastases, however, especially to bone. [6] Although a single risk-classification strategy is unavailable, these criteria should guide physicians to use therapeutic strategies that are directed toward the particular disease and risk for an individual patient, rather than applying a general treatment strategy for all patients with a particular form of thyroid carcinoma. More recent management guidelines from the American Thyroid Association (ATA) have recommended use of the AJCC/UICC staging system for all patients with differentiated thyroid cancer.

THYROID CANCER. I. Introduction

THYROID CANCER. I. Introduction THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in

More information

Recurrent & Persistent Papillary Thyroid Cancer Central Nodal Dissection vs. Node-Picking Patterns of Nodal Metastases Recurrent Laryngeal Nerve,

Recurrent & Persistent Papillary Thyroid Cancer Central Nodal Dissection vs. Node-Picking Patterns of Nodal Metastases Recurrent Laryngeal Nerve, Recurrent & Persistent Papillary Thyroid Cancer Central Nodal Dissection vs. Node-Picking Patterns of Nodal Metastases Recurrent Laryngeal Nerve, Larynx, Trachea, & Esophageal Management Robert C. Wang,

More information

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:

More information

TNM Staging of Head and Neck Cancer and Neck Dissection Classification

TNM Staging of Head and Neck Cancer and Neck Dissection Classification QUICK REFERENCE GUIDE TO TNM Staging of Head and Neck Cancer and Neck Dissection Classification Fourth Edition 2014 All materials in this ebook are copyrighted by the American Academy of Otolaryngology

More information

Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery

Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David

More information

Advances in Differentiated Thyroid Cancer

Advances in Differentiated Thyroid Cancer Advances in Differentiated Thyroid Cancer Steven A. De Jong, M.D., FACS, FACE Professor and Vice Chair Clinical Affairs Department of Surgery Loyola University Medical Center Thyroid Cancer classification

More information

Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科

Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)

More information

Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD

Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence Cord Sturgeon, MD Associate Professor of Surgery Northwestern University Feinberg School of Medicine Director of Endocrine Surgery Chicago,

More information

Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment

Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment Michele Klain, Marco Salvatore Department of Functional and Biomorphological Science University of Naples "Federico

More information

Staging Head and Neck Cancers Transitioning to the Seventh Edition of The AJCC Cancer Staging Manual

Staging Head and Neck Cancers Transitioning to the Seventh Edition of The AJCC Cancer Staging Manual Staging Head and Neck Cancers Transitioning to the Seventh Edition of The AJCC Cancer Staging Manual Jatin P. Shah, MD, PhD (Hon) Memorial Sloan-Kettering Cancer Center New York, New York The American

More information

Management of Differentiated Thyroid Carcinoma American Thyroid Association Guidelines and Data from Kaohsiung Chang Gung Memorial Hospital

Management of Differentiated Thyroid Carcinoma American Thyroid Association Guidelines and Data from Kaohsiung Chang Gung Memorial Hospital Review Management of Differentiated Thyroid Carcinoma American Thyroid Association Guidelines and Data from Kaohsiung Chang Gung Memorial Hospital Pei-Wen Wang Abstract Background. Most thyroid cancers

More information

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium European Journal of Endocrinology (2006) 154 787 803 ISSN 0804-4643 CONSENSUS STATEMENT European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

More information

Thyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules)

Thyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules) Thyroid Differentiated Cancer: Does Size Really Count? (New ways to evaluate thyroid nodules) Jeffrey S. Freeman, D.O., F.A.C.O.I. Chairman, Division of Endocrinology and Metabolism Philadelphia College

More information

Thyroid Cancer. What is thyroid cancer? The thyroid gland

Thyroid Cancer. What is thyroid cancer? The thyroid gland Thyroid Cancer What is thyroid cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer, and can spread to other areas of the body.

More information

Thyroid Cancer Diagnosis and Management. Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010

Thyroid Cancer Diagnosis and Management. Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010 Thyroid Cancer Diagnosis and Management Jerome Hershman, M.D. Internal Medicine Grand Rounds University of Missouri, Columbia October 21, 2010 DISCLOSURE NOTHING TO DISCLOSE in regard to financial conflict

More information

A912: Kidney, Renal cell carcinoma

A912: Kidney, Renal cell carcinoma A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type

More information

Thyroid and Adrenal Gland

Thyroid and Adrenal Gland Thyroid and Adrenal Gland NAACCR 2011 2012 Webinar Series 12/1/11 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar

More information

Thyroid Cancer. What is cancer?

Thyroid Cancer. What is cancer? What is cancer? Thyroid Cancer The body is made up of hundreds of millions of living cells. Normal body cells grow, divide to make new cells, and die in an orderly fashion. During the early years of a

More information

Diagnosis and Prognosis of Pancreatic Cancer

Diagnosis and Prognosis of Pancreatic Cancer Main Page Risk Factors Reducing Your Risk Screening Symptoms Diagnosis Treatment Overview Chemotherapy Radiation Therapy Surgical Procedures Lifestyle Changes Managing Side Effects Talking to Your Doctor

More information

Kidney Cancer OVERVIEW

Kidney Cancer OVERVIEW Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney

More information

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer THYROID Volume 16, Number 2, 2006 American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Taskforce*

More information

Followup of Patients with Papillary Thyroid Cancer: In Search of the Optimal Algorithm

Followup of Patients with Papillary Thyroid Cancer: In Search of the Optimal Algorithm Followup of Patients with Papillary Thyroid Cancer: In Search of the Optimal Algorithm Elizabeth A Mittendorf, MD, Xuemei Wang, MS, Nancy D Perrier, MD, Ashleigh M Francis, BSPH, Beth S Edeiken, MD, Suzanne

More information

After reviewing this module, the student will have the ability to:

After reviewing this module, the student will have the ability to: LEARNING OBJECTIVES After reviewing this module, the student will have the ability to: - Approach History & physical exam of patients with thyroid pathology - Understand which patients require surgery

More information

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma. Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of

More information

Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma

Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma Latest Oncologic Strategies for Well-Differentiated Thyroid Carcinoma April 2008 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor of Surgery and Medicine David Geffen School of

More information

Well-differentiated Thyroid Carcinoma: Factors Predicting Recurrence and Survival

Well-differentiated Thyroid Carcinoma: Factors Predicting Recurrence and Survival Singapore Med J 2002 Vol 43(9) : 457-462 O r i g i n a l A r t i c l e Well-differentiated Thyroid Carcinoma: Factors Predicting Recurrence and Survival L H Y Lim, K C Soo, Y K Chong, F Gao, G S Hong,

More information

Management of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed

Management of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed Management of Well Differentiated Thyroid Cancers: Where We Have Been and Where We are Headed Medical Grand Rounds December 10,2015 Christine Signore, MD ECNU Learning Objectives Discuss the epidemiology

More information

Review Article To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients

Review Article To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients Hindawi Publishing Corporation Journal of Oncology Volume 2012, Article ID 707156, 11 pages doi:10.1155/2012/707156 Review Article To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in

More information

BRAF as a prognostic marker in papillary thyroid cancer

BRAF as a prognostic marker in papillary thyroid cancer 12 Congresso Nazionale AME Molecular markers in thyroid cancer: current role in clinical practice BRAF as a prognostic marker in papillary thyroid cancer Dott. ssa Cristina Romei Sezione di Endocrinologia

More information

Hurthle Cell Thyroid Carcinoma During Pregnancy: A Case Presentation and Literature Review M. W. Love and M.D. Reed, MD

Hurthle Cell Thyroid Carcinoma During Pregnancy: A Case Presentation and Literature Review M. W. Love and M.D. Reed, MD Hurthle Cell Thyroid During Pregnancy: A Case Presentation and Literature Review M. W. Love and M.D. Reed, MD Introduction Thyroid carcinoma (TC), the most common endocrine malignancy, has been shown to

More information

AACE/AAES MEDICAL/SURGICAL GUIDELINES FOR CLINICAL PRACTICE: MANAGEMENT OF THYROID CARCINOMA

AACE/AAES MEDICAL/SURGICAL GUIDELINES FOR CLINICAL PRACTICE: MANAGEMENT OF THYROID CARCINOMA AACE/AAES MEDICAL/SURGICAL GUIDELINES FOR CLINICAL PRACTICE: MANAGEMENT OF THYROID CARCINOMA Thyroid Carcinoma Task Force Co-Chairpersons Rhoda H. Cobin, MD, FACE Hossein Gharib, MD, FACP, FACE Committee

More information

DIAGNOSIS OF PROSTATE CANCER

DIAGNOSIS OF PROSTATE CANCER DIAGNOSIS OF PROSTATE CANCER Determining the presence of prostate cancer generally involves a series of tests and exams. Before starting the testing process, the physician will ask questions about the

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used? Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or

More information

Preventable reoperations for persistent and recurrent papillary thyroid carcinoma

Preventable reoperations for persistent and recurrent papillary thyroid carcinoma Preventable reoperations for persistent and recurrent papillary thyroid carcinoma Maria A. Kouvaraki, MD, PhD, Jeffrey E. Lee, MD, Suzanne E. Shapiro, MS, Steven I. Sherman, MD, and Douglas B. Evans, MD,

More information

Cancer of the Thyroid Explained

Cancer of the Thyroid Explained Cancer of the Thyroid Explained Patient Information Introduction This leaflet tells you about the condition known as thyroid cancer. We hope it will answer some of the questions that you or those who care

More information

Papillary Thyroid Cancer: Controversies in the Management of Neck Metastasis

Papillary Thyroid Cancer: Controversies in the Management of Neck Metastasis The Laryngoscope Lippincott Williams & Wilkins 2008 The American Laryngological, Rhinological and Otological Society, Inc. Papillary Thyroid Cancer: Controversies in the Management of Neck Metastasis H.

More information

Current Treatment of Papillary Thyroid Microcarcinoma

Current Treatment of Papillary Thyroid Microcarcinoma Advances in Surgery 46 (2012) 191 203 ADVANCES IN SURGERY Current Treatment of Papillary Thyroid Microcarcinoma Xiao-Min Yu, MD, PhD a, Ricardo Lloyd, MD, PhD b, Herbert Chen, MD c, * a Department of Surgery,

More information

WELL DIFFERENTIATED THYROID CANCER

WELL DIFFERENTIATED THYROID CANCER Scandinavian Journal of Surgery 93: 261 271, 2004 WELL DIFFERENTIATED THYROID CANCER N. R. Caron, O. H. Clark Department of Surgery, University of California, San Francisco and UCSF Comprehensive Cancer

More information

Chapter 2 Staging of Breast Cancer

Chapter 2 Staging of Breast Cancer Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination

More information

Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.

Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors. Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)

More information

how? Managing thyroid cancer with Thyrogen (thyrotropin alfa for injection) 0.9 mg/ml

how? Managing thyroid cancer with Thyrogen (thyrotropin alfa for injection) 0.9 mg/ml how? Managing thyroid cancer with Thyrogen (thyrotropin alfa for injection) 0.9 mg/ml Introduction You received this booklet because your doctor wants you to know about Thyrogen (thyrotropin alfa for injection),

More information

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof

More information

Oxford Centre for Head and Neck Oncology The Thyroid Gland and Thyroid Cancer Information for patients

Oxford Centre for Head and Neck Oncology The Thyroid Gland and Thyroid Cancer Information for patients Oxford University Hospitals NHS Trust Oxford Centre for Head and Neck Oncology The Thyroid Gland and Thyroid Cancer Information for patients What is the thyroid gland? The thyroid gland is an endocrine

More information

Understanding Metastatic Disease

Understanding Metastatic Disease Supported by an unrestricted educational grant from Pfizer Understanding Metastatic Disease Metastatic disease or metastases are phrases that mean the same as Secondary cancer. This means that the cancer

More information

Predictive value of braf V600E mutational analysis in patients with differentiated thyroid cancer (DTC) submitted to radioiodine treatment (RAI)

Predictive value of braf V600E mutational analysis in patients with differentiated thyroid cancer (DTC) submitted to radioiodine treatment (RAI) Predictive value of braf V600E mutational analysis in patients with differentiated thyroid cancer (DTC) submitted to radioiodine treatment (RAI) D.A. Pizzuto1, S. Annunziata1, C. Brunelli2, G. Perotti1,

More information

Renal Cancer: Symptoms, diagnosis, pathology & prognosis

Renal Cancer: Symptoms, diagnosis, pathology & prognosis Renal Cancer: Symptoms, diagnosis, pathology & prognosis Mark Johnson Consultant Urological Surgeon Newcastle upon Tyne Hospitals NHS Foundation Trust Plan for today: How renal tumours present What investigations

More information

A918: Prostate: adenocarcinoma

A918: Prostate: adenocarcinoma A918: Prostate: adenocarcinoma General facts of prostate cancer The prostate is about the size of a walnut. It is just below the bladder and in front of the rectum. The tube that carries urine (the urethra)

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

0021-972X/97/$03.00/0 Vol. 82, No. 11 Journal of Clinical Endocrinology and Metabolism Copyright 1997 by The Endocrine Society

0021-972X/97/$03.00/0 Vol. 82, No. 11 Journal of Clinical Endocrinology and Metabolism Copyright 1997 by The Endocrine Society 0021-972X/97/$03.00/0 Vol. 82, No. 11 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society Pathological Tumor-Node-Metastasis (ptnm) Staging for Papillary

More information

Newly Diagnosed Prostate Cancer: Understanding Your Risk

Newly Diagnosed Prostate Cancer: Understanding Your Risk Newly Diagnosed Prostate Cancer: Understanding Your Risk When the urologist calls with the life-changing news that your prostate biopsy is positive for prostate cancer, an office appointment is made to

More information

Thyroid Cancer A Multidisciplinary Approach

Thyroid Cancer A Multidisciplinary Approach Thyroid Cancer A Multidisciplinary Approach Shuvendu Sen, MD, MS, FACP Associate Program Director, Internal Medicine Residency Program Director, Medical Education Raritan Bay Medical Center, Rutgers University

More information

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent

More information

H ODGKIN AND NON-HODGKIN LYMPHOMA STAGING FORM

H ODGKIN AND NON-HODGKIN LYMPHOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery PRIMARY TUMOR (T) No T category exists for Hodgkin and Non-Hodgkin Lymphoma

More information

Thyroid Cancer Finding It and Treating It Using Radioiodine

Thyroid Cancer Finding It and Treating It Using Radioiodine Thyroid Cancer Finding It and Treating It Using Radioiodine Your doctor has referred you to Nuclear Medicine to learn more about the extent of your thyroid cancer, and perhaps even for treatment of the

More information

The TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK

The TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.

More information

PET/CT for Melanoma. Sarajevo (Bosnia & Hercegovina) Wednesday, June :40 10:20

PET/CT for Melanoma. Sarajevo (Bosnia & Hercegovina) Wednesday, June :40 10:20 Sarajevo (Bosnia & Hercegovina) Wednesday, June 18 2014 09:40 10:20 PET/CT for Melanoma The Trundholm Sun Chariot, anterior view app 1350 BC The National Museum of Denmark, Copenhagen 54 x 35 x 29 cm (width,

More information

Thyroglobulin. versie 071120 J. Billen LAG-UZ-KULeuven 1

Thyroglobulin. versie 071120 J. Billen LAG-UZ-KULeuven 1 Thyroglobulin Large glycoprotein Two identical polypeptide chains 660 kda Prohormone in the intra-thyroid T4 and T3 synthesis Produced only by normal thyrocytes or well-differentiated thyroid cancer (DTC)

More information

Influence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma

Influence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma ORIGINAL ARTICLE Influence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma Jasna Mihailovic, MD, PhD,*Þ Ljubomir Stefanovic, MD, PhD,* and Ranka

More information

EMR Can anyone do this?

EMR Can anyone do this? EMR Can anyone do this? Norio Fukami, MD University of Colorado Piecemeal resection? 1 Endoscopic mucosal resection (EMR) and Endoscopic submucosal dissection (ESD) Endoscopic removal of premalignant or

More information

Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method

Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method Christopher Martel, M.Sc., CHP Lisa Thornhill,, NRRPT, RT(NM) Boston University Medical Center Thyroid Carcinoma New cases and deaths in

More information

Sonographic Findings in the Surgical Bed After Thyroidectomy

Sonographic Findings in the Surgical Bed After Thyroidectomy Article Sonographic Findings in the Surgical Bed After Thyroidectomy Comparison of Recurrent Tumors and Nonrecurrent Lesions Jung Hee Shin, MD, Boo-Kyung Han, MD, Eun Young Ko, MD, Seok Seon Kang, MD Objective.

More information

Thyroid nodules. John Chaplin. Nick McIvor. Auckland Head and Neck Associates. Auckland Head & Neck Associates

Thyroid nodules. John Chaplin. Nick McIvor.   Auckland Head and Neck Associates. Auckland Head & Neck Associates Thyroid nodules John Chaplin www.thyroid.co.nz Nick McIvor www.neck.co.nz Head and Neck Thyroid Nodules Common 3-5% palpable 50-70% ultrasound Increase with age More in women 90-95% benign Head and Neck

More information

Liver Cancer What is the liver? What is liver cancer?

Liver Cancer What is the liver? What is liver cancer? Liver Cancer What is the liver? The liver is the largest internal organ in the body and is important in digesting food. The liver performs many other functions, including collecting and filtering blood

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Adjuvant Therapy for Breast Cancer: Questions and Answers

Adjuvant Therapy for Breast Cancer: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast

More information

Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine

Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine Douglas Van Nostrand, MD, FACP, FACNM Director, Nuclear Medicine

More information

2, 2007 RESIDENT PHYSICIAN:

2, 2007 RESIDENT PHYSICIAN: TITLE: Management of Invasive Thyroid Carcinoma SOURCE: Grand Rounds Presentation, UTMB, Dept. of Otolaryngology DATE: May 2, 2007 RESIDENT PHYSICIAN: Camysha Wright, MD FACULTY ADVISOR: Vicente Resto,

More information

See MP/H rules on the slides if you do not have your manual.

See MP/H rules on the slides if you do not have your manual. Quiz 1 1. Which of the following statements about the incidence of melanoma in the US over the last 30 years is true? a. Melanoma incidences have been going down for both men and women. b. Melanoma incidences

More information

Us TOO University Presents: Understanding Diagnostic Testing

Us TOO University Presents: Understanding Diagnostic Testing Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by

More information

Lung Cancer: Practical Application of Imaging In Determining Resectability. Jeremy J. Erasmus, M. D.

Lung Cancer: Practical Application of Imaging In Determining Resectability. Jeremy J. Erasmus, M. D. Lung Cancer: Practical Application of Imaging In Determining Resectability Jeremy J. Erasmus, M. D. 62 year old man with a superior sulcus tumor. Which of the following precludes surgical resection in

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D. Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are

More information

Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006

Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006 Multiple Myeloma Figure 16 Definition: Multiple myeloma forms in plasma cells that are normally found in the bone marrow. 1 The plasma cells grow out of control and form tumors (plasmacytoma) or crowd

More information

For further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer.

For further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer. Prostate Cancer For many older men, prostate cancer may be present but never cause symptoms or problems and many men will die with their prostate cancer rather than of their prostate cancer. Yet it remains

More information

PATIENT GUIDE. Localized Prostate Cancer

PATIENT GUIDE. Localized Prostate Cancer PATIENT GUIDE Localized Prostate Cancer The prostate* is part of the male reproductive system. It is about the same size as a walnut and weighs about an ounce. As pictured in Figure 1, the prostate is

More information

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

More information

Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin

Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin E L Mazzaferri 1 and N Massoll 2 1 Adjunct Professor of Medicine, University of

More information

Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated? An Analysis of 18,445 Cases

Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated? An Analysis of 18,445 Cases PAPERS OF THE 131ST ASA ANNUAL MEETING Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated? An Analysis of 18,445 Cases Xiao-Min Yu, MD, PhD, Yin Wan, MS, Rebecca S. Sippel, MD, FACS,

More information

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid

More information

Thyroid Carcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2014. NCCN.org. Continue

Thyroid Carcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2014. NCCN.org. Continue NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2014 NCCN.org Continue Version 2.2014, 08/12/2014 National Comprehensive Cancer Network, Inc. 2014, All rights reserved. The NCCN

More information

PET/CT in Lung Cancer

PET/CT in Lung Cancer PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT

More information

Pediatric Oncology for Otolaryngologists

Pediatric Oncology for Otolaryngologists Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department

More information

A Brief Outline of Prostate Cancer

A Brief Outline of Prostate Cancer A Brief Outline of Prostate Cancer Assessment of Prognostic Factors to Assist in Therapeutic Choices Courtesy of Molecular Oncology International Introduction and Background Newer advances in the molecular

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Papillary Thyroid Cancer with Chest Metastases Only Detected Using Radioactive Iodine

Papillary Thyroid Cancer with Chest Metastases Only Detected Using Radioactive Iodine Original Article 663 Papillary Thyroid Cancer with Chest Metastases Only Detected Using Radioactive Iodine Sheng-Fong Kuo, MD; Szu-Tah Chen, MD, PhD; Pan-Fu Kao 1, MD; Yu-Chen Chang 1, MD; Shuo-Chi Chou,

More information

A Practical Guide to Advances in Staging and Treatment of NSCLC

A Practical Guide to Advances in Staging and Treatment of NSCLC A Practical Guide to Advances in Staging and Treatment of NSCLC Robert J. Korst, M.D. Director, Thoracic Surgery Medical Director, The Blumenthal Cancer Center The Valley Hospital Objectives Revised staging

More information

Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer

Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer Thyroid Science 5(1):CLS1-8, 2010 www.thyroidscience.com Clinical and Laboratory Studies Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer 1 2 5 Aruna Turaka, MD, Tianyu Li, MS, Jian Q. Yu,

More information

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in

More information

Understanding Your Breast Cancer Pathology Report *

Understanding Your Breast Cancer Pathology Report * Understanding Your Breast Cancer Pathology Report * * Note: Your pathology report may contain all or some of the sections covered in this guide. Remember, your healthcare team is always available to help

More information

UICC World Cancer Congress. Cancer Staging and Quality of Care

UICC World Cancer Congress. Cancer Staging and Quality of Care UICC World Cancer Congress August 27 30, 2012, Montreal CANCER STAGE: A neglected cornerstone of Cancer Control Cancer Staging and Quality of Care Christian Wittekind Institut für Pathologie UKL 1 Agenda!

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies

More information

IV. DEFINITION OF LYMPH NODE GROUPS (FIGURE 1) Level IA: Submental Group

IV. DEFINITION OF LYMPH NODE GROUPS (FIGURE 1) Level IA: Submental Group IV. DEFINITION OF LYMPH NODE GROUPS (FIGURE 1) Fig. 1 The level system is used for describing the location of lymph nodes in the neck: Level I, submental and submandibular group; Level II, upper jugular

More information

M ALIGNANT MELANOMA OF THE UVEA STAGING FORM

M ALIGNANT MELANOMA OF THE UVEA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX T0 a a a d b c d a TUMOR SIZE: S TAGE C ATEGORY D EFINITIONS LATERALITY:

More information

Ovarian Cancer. Josie Rutovitz

Ovarian Cancer. Josie Rutovitz Ovarian Cancer Josie Rutovitz Extent of the Problem In 2006 = 9 th most common cancer in women (Aust Institute of Health and Welfare). 1226 new cases in 2006. 60% of cases are post menopausal. 47% increase

More information

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500

More information

TNM STAGING OF HEAD AND NECK CANCER AND NECK DISSECTION CLASSIFICATION

TNM STAGING OF HEAD AND NECK CANCER AND NECK DISSECTION CLASSIFICATION Pocket Guide To TNM STAGING OF HEAD AND NECK CANCER AND NECK DISSECTION CLASSIFICATION Edited by Daniel G. Deschler, MD Terry Day, MD AAO HNS/F American Head and Neck Society Pocket Guide to NECK DISSECTION

More information